The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Glivec

400 milligram(s) Coated tablet

Novartis Europharm LimitedEU/1/01/198/010

Main Information

Trade NameGlivec
Active SubstancesImatinib mesilate
Strength400 milligram(s)
Dosage FormCoated tablet
Licence HolderNovartis Europharm Limited
Licence NumberEU/1/01/198/010

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE01 imatinib

Status

Authorised/WithdrawnAuthorised
Licence Issued11/11/2003
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back